Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00653757 | Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer | completed | Phase 1 / Phase 2 | 100 | Mayo ClinicOTHER | 1 | Mar 19, 2012 | clinicaltrials |
| NCT00731848 | Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer | unknown | Phase 2 | 30 | Roll International CorporationINDUSTRY | 1 | Mar 16, 2012 | clinicaltrials |
| NCT00732043 | Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer | unknown | Phase 2 | 200 | Roll International CorporationINDUSTRY | 1 | Mar 16, 2012 | clinicaltrials |
| NCT00083005 | Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate | completed | Phase 2 | 60 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT01340599 | Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery | terminated | Phase 2 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 15, 2012 | clinicaltrials |
| NCT01132599 | Comparing PET-CT Using C-11 Choline and 18F-Fluoromethylcholine in Patients With Metastatic Prostate Cancer | withdrawn | Phase 2 | 0 | Cancer Research UKOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT00242918 | Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer | completed | Phase 2 | 29 | Benaroya Research InstituteOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00736164 | Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Feb 6, 2012 | clinicaltrials |
| NCT01132404 | Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 | terminated | Phase 1 / Phase 2 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 31, 2012 | clinicaltrials |
| NCT00126165 | Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 72 | Alberta Health servicesOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00116779 | A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer | completed | Phase 2 | 127 | Ferring PharmaceuticalsINDUSTRY | 2 | Dec 19, 2011 | clinicaltrials |
| NCT01487902 | The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer | unknown | Phase 2 | 90 | Asan Medical CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
| NCT00550810 | Sutent Maintenance After Response to Taxotere(SMART) | unknown | Phase 2 | 30 | Alberta Health servicesOTHER | 1 | Dec 7, 2011 | clinicaltrials |
| NCT01153113 | Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines | withdrawn | Phase 1 / Phase 2 | 0 | University of FloridaOTHER | 0 | Dec 2, 2011 | clinicaltrials |
| NCT00973882 | Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers | completed | Phase 2 | 60 | Centre Leon BerardOTHER | 1 | Nov 3, 2011 | clinicaltrials |
| NCT00005857 | Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy | completed | Phase 2 | — | City of Hope Medical CenterOTHER | 1 | Oct 20, 2011 | clinicaltrials |
| NCT00036075 | Study Using CP-461 to Treat Advanced Prostate Cancer | completed | Phase 2 | 25 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00129025 | Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 35 | Alberta Health servicesOTHER | 1 | Oct 10, 2011 | clinicaltrials |
| NCT00741364 | Vitamin D Effects on Prostate Pathology(DProstate) | unknown | Phase 2 | 90 | University of TorontoOTHER | 1 | Sep 30, 2011 | clinicaltrials |
| NCT00452387 | Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) | terminated | Phase 2 | 22 | Accelerated Community Oncology Research NetworkOTHER | 1 | Sep 16, 2011 | clinicaltrials |
| NCT01409876 | HistScanning- Based PDR Brachytherapy in Prostate Cancer HistoScanning- Based Interstitial PDR Brachytherapy | unknown | Phase 2 | 100 | University Hospital ErlangenOTHER | 1 | Aug 4, 2011 | clinicaltrials |
| NCT00286793 | Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC | completed | Phase 1 / Phase 2 | 76 | Ascenta TherapeuticsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00148772 | Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy | completed | Phase 2 | 29 | Endeavor HealthOTHER | 1 | Jun 28, 2011 | clinicaltrials |
| NCT00050596 | Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer | completed | Phase 2 | — | Bristol-Myers SquibbINDUSTRY | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00651417 | Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue | unknown | Phase 2 | 101 | Arizona Oncology ServicesOTHER | 1 | Jun 23, 2011 | clinicaltrials |
| NCT01225471 | Novel Peptide Vaccination for Patients With Advanced Prostate Cancer | unknown | Phase 1 / Phase 2 | 30 | Iwate Medical UniversityOTHER | 1 | Jun 23, 2011 | clinicaltrials |
| NCT00134654 | Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer | completed | Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 16, 2011 | clinicaltrials |
| NCT00268593 | Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer | completed | Phase 2 | 48 | Progen PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT00069888 | A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy | completed | Phase 2 | 83 | SanofiINDUSTRY | 1 | Jun 8, 2011 | clinicaltrials |
| NCT00117312 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | terminated | Phase 2 | 37 | Ferring PharmaceuticalsINDUSTRY | 1 | May 23, 2011 | clinicaltrials |
| NCT00117949 | Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486 | completed | Phase 2 | 82 | Ferring PharmaceuticalsINDUSTRY | 1 | May 23, 2011 | clinicaltrials |
| NCT00215657 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | terminated | Phase 2 | 131 | Ferring PharmaceuticalsINDUSTRY | 0 | May 20, 2011 | clinicaltrials |
| NCT00245466 | Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients | terminated | Phase 2 | 88 | Ferring PharmaceuticalsINDUSTRY | 0 | May 20, 2011 | clinicaltrials |
| NCT00554086 | Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.(CHICS) | completed | Phase 2 | 65 | Canadian Urology Research ConsortiumOTHER | 1 | May 16, 2011 | clinicaltrials |
| NCT00627354 | Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 90 | Groupe D'Etude des Tumeurs Uro-GenitalesOTHER | 1 | May 16, 2011 | clinicaltrials |
| NCT00002506 | Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer | completed | Phase 2 | — | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 12, 2011 | clinicaltrials |
| NCT00193271 | Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer | completed | Phase 2 | 30 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00468286 | Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy | completed | Phase 2 | 133 | Ferring PharmaceuticalsINDUSTRY | 5 | Mar 23, 2011 | clinicaltrials |
| NCT00716794 | A Phase I/II Study of HE3235 in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 64 | Harbor TherapeuticsINDUSTRY | 1 | Mar 9, 2011 | clinicaltrials |
| NCT00054522 | Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy | completed | Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Mar 8, 2011 | clinicaltrials |
| NCT00006114 | Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | unknown | Phase 2 | — | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Mar 1, 2011 | clinicaltrials |
| NCT00319787 | Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer | completed | Phase 2 | 102 | AstraZenecaINDUSTRY | 1 | Jan 25, 2011 | clinicaltrials |
| NCT00637871 | Casodex - Nolvadex Combination | completed | Phase 2 | — | AstraZenecaINDUSTRY | 0 | Jan 24, 2011 | clinicaltrials |
| NCT00577356 | Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer | terminated | Phase 2 | 6 | Benaroya Research InstituteOTHER | 1 | Jan 20, 2011 | clinicaltrials |
| NCT00268892 | Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer | completed | Phase 2 / Phase 3 | 278 | Ferring PharmaceuticalsINDUSTRY | 10 | Dec 24, 2010 | clinicaltrials |
| NCT00252941 | Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma | completed | Phase 1 / Phase 2 | 20 | The Cleveland ClinicOTHER | 1 | Dec 21, 2010 | clinicaltrials |
| NCT00116753 | A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer | completed | Phase 2 | 460 | Ferring PharmaceuticalsINDUSTRY | 11 | Dec 10, 2010 | clinicaltrials |
| NCT00004014 | Liposomal Doxorubicin in Treating Patients With Prostate Cancer | completed | Phase 2 | 10 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 16, 2010 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT00430235 | A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer | completed | Phase 2 | 39 | British Columbia Cancer AgencyOTHER | 1 | Aug 5, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Mar 19, 2012source: clinicaltrials